Posted by Michael Wonder on 14 Jul 2020
PMPRB changes within scope of Patent Act, rules federal court in judicial review
13 July 2020 - The Federal Court has upheld reforms to the Patented Medicines Pricing Review Board that updated the board’s reference countries for drug pricing and required it to review three new economic factors when determining whether patented medicines are excessively priced.
The court ruled against an argument by Innovative Medicines Canada and 16 pharmaceutical companies in their application for judicial review that the changes fell outside the scope of the Patent Act, which governs the PMPRB.
